Lexicon to Present at the BIO 2007 International Convention
May 07 2007 - 7:30AM
PR Newswire (US)
THE WOODLANDS, Texas, May 7 /PRNewswire-FirstCall/ -- Lexicon
Pharmaceuticals, Inc. (NASDAQ:LXRX) announced today that Arthur T.
Sands, M.D., Ph.D., Lexicon's president and chief executive
officer, will present at the BIO 2007 International Convention at
the Boston Convention Center, Boston, Massachusetts on Wednesday,
May 9, 2007 at 9:15 a.m. Eastern Time. Dr. Sands will participate
in the Business Forum under the Drug Discovery category and provide
an overview of Lexicon's clinical and preclinical development
programs, collaborations and corporate objectives for 2007. About
Lexicon Lexicon is a biopharmaceutical company focused on the
discovery and development of breakthrough treatments for human
disease. Lexicon currently has clinical programs underway for such
areas of major unmet medical need as irritable bowel syndrome and
cognitive disorders. The company has used its proprietary gene
knockout technology to discover more than 100 promising drug
targets and create an extensive pipeline of clinical and
preclinical programs in the therapeutic areas of diabetes and
obesity, cardiovascular disease, psychiatric and neurological
disorders, cancer, immune system disorders and ophthalmic disease.
To advance the development and commercialization of its programs,
Lexicon is working both independently and through collaborators
including Bristol-Myers Squibb Company, Genentech, Inc., N.V.
Organon and Takeda Pharmaceutical Company Limited. For additional
information about Lexicon and its programs, please visit
http://www.lexpharma.com/ . Safe Harbor Statement This press
release contains "forward-looking statements," including statements
relating to Lexicon's plans regarding regulatory filings and
clinical development programs for LX6171 and LX1031 and the
potential therapeutic and commercial potential of LX6171 and LX1031
and other potential drug candidates in Lexicon's preclinical
pipeline. This press release also contains forward-looking
statements relating to Lexicon's growth and future operating
results, discovery and development of products, strategic alliances
and intellectual property, as well as other matters that are not
historical facts or information. All forward-looking statements are
based on management's current assumptions and expectations and
involve risks, uncertainties and other important factors,
specifically including those relating to Lexicon's ability to
successfully conduct clinical development of LX6171 and LX1031 and
preclinical development of other potential drug candidates, advance
additional candidates into preclinical and clinical development,
obtain necessary regulatory approvals, achieve its operational
objectives, obtain patent protection for its discoveries and
establish strategic alliances, as well as additional factors
relating to manufacturing, intellectual property rights, and the
therapeutic or commercial value of its drug candidates, that may
cause Lexicon's actual results to be materially different from any
future results expressed or implied by such forward-looking
statements. Information identifying such important factors is
contained under "Factors Affecting Forward-Looking Statements" and
"Risk Factors" in Lexicon's annual report on Form 10-K for the year
ended December 31, 2006, as filed with the Securities and Exchange
Commission. Lexicon undertakes no obligation to update or revise
any such forward-looking statements, whether as a result of new
information, future events or otherwise. DATASOURCE: Lexicon
Pharmaceuticals, Inc. CONTACT: Bobbie Faulkner, Investor Relations
of Lexicon Pharmaceuticals, Inc., +1-281-863-3503, or Web site:
http://www.lexpharma.com/
Copyright
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024